Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: September 16, 2026
Context: The Company is addressing a Nasdaq listing compliance issue triggered by the accounting treatment of "Milestone Warrants" issued in connection with the June 2026 acquisition of Azora Therapeutics, Inc. and a concurrent PIPE financing. The classification of these warrants as a liability caused stockholders' equity to fall below Nasdaq Capital Market minimum requirements.
Key Financial Metrics and Capital Structure
Revenue, Profit, and Cash Flow: The filing does not provide specific revenue, profit, or cash flow figures for the reporting period. It references the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, for historical financial data.
Capital Structure and Equity:
- Equity Status: Stockholders' equity fell below Nasdaq minimum listing requirements as of June 30, 2026, due to the liability classification of Milestone Warrants.
- Merger Consideration (June 2026): Issued 437,474 shares of Common Stock and 12,930.617 shares of Series A Non-Voting Convertible Preferred Stock (convertible into 1,000 shares of Common Stock each) to Azora stockholders.
- PIPE Financing: Issued pre-funded warrants to purchase 9,749,345 shares of Common Stock to PIPE Investors.
- Note Exchange: Issued pre-funded warrants to purchase 2,031,603 shares of Common Stock to former Azora note holders in exchange for extinguishing $5,500,000 in guaranteed notes.
- Milestone Warrants: Investors hold rights to purchase up to 11,780,946 additional shares of Common Stock via Milestone Pre-Funded Warrants and Common Warrants at a combined price of $2.7489 per set.
Material Changes and Actions
Amendments to Agreements (September 16, 2026):
- Removal of Penalty Provision: The Company entered into Amendment No. 2 to the Securities Purchase Agreement and Amendment No. 1 to the Note Exchange Agreement. These amendments removed the "Penalty Provision," which previously reduced an investor's right to purchase Milestone Warrants if they exercised Initial Closing Pre-Funded Warrants early.
- Accounting Impact: The removal of the Penalty Provision changes the accounting treatment of the Milestone Warrants from a liability to equity. This adjustment is intended to restore stockholders' equity to levels compliant with Nasdaq listing standards.
- Lock-Up Provisions: In exchange for removing the Penalty Provision, the amendments added lock-up periods prohibiting PIPE Investors and Former Azora Noteholders from selling shares issuable upon exercise of their Initial Closing Pre-Funded Warrants for a specified period.
Outlook, Risks, and Management Commentary
Upcoming Corporate Actions:
- Annual Meeting: Scheduled for September 17, 2026. Stockholders will vote on the issuance of Common Stock upon conversion of Series A Preferred Stock.
- Change in Control: The conversion of Series A Preferred Stock will result in a change of control under Nasdaq Listing Rules 5635(a) and 5635(b) and will represent more than 19.99% of shares outstanding prior to the Merger Agreement.
Risks and Contingencies:
- Pro Forma Limitations: The Company filed unaudited pro forma condensed balance sheets reflecting the accounting changes. Management notes these are for illustrative purposes only and may not accurately reflect the actual financial condition following the conversion and amendments due to unreflected costs and assumptions.
- Listing Compliance: The primary risk addressed is the potential delisting from the Nasdaq Capital Market due to insufficient stockholders' equity, which the amendments aim to resolve.
Investor Verification Checklist
- Verify the successful approval of the Series A Preferred Stock conversion at the Annual Meeting on September 17, 2026.
- Confirm that the amended agreements have been accepted by all relevant Former Azora Noteholders (the filing notes the Company intends to amend agreements with additional note holders in the near term).
- Review the unaudited pro forma condensed balance sheet (Exhibit 99.1) to assess the projected equity position post-amendment.
- Monitor Nasdaq's official communication regarding the Company's compliance status following the accounting adjustment.
- Check the specific duration and exceptions of the new lock-up periods imposed on PIPE Investors and Noteholders.